Genetic heterogeneity limits presymptomatic DNA testing for malignant hyperthermia to families with proven linkage to chromosome 19q13.1-13.2.
Answers are grounded in this paper and cite their sources.
Restricts presymptomatic DNA testing for malignant hyperthermia to linked families; leaves open broader gene discovery.
Malignant hyperthermia susceptibility remains the commonest cause of death owing to general anaesthesia. This is despite the availability of presymptomatic testing, admittedly by a highly invasive method, and a recognised treatment for implementation immediately a patient shows signs of developing a crisis. Recently the finding of linkage to markers from chromosome 19q13.1-13.2 and the identification of mutations in a candidate gene held out hope of genetic diagnosis being available. However, it is likely that only about 50% of families have a mutation of the skeletal muscle calcium release channel gene. With this degree of genetic heterogeneity, presymptomatic testing based on DNA markers can only be offered at present to a limited number of families where linkage to markers from 19q13.1-13.2 has been clearly shown.
No takes yet. Share an insight, caveat, or question.
Ball et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: